Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 Gennaio 2023 - 3:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of January 2023
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BiondVax
Pharmaceuticals Ltd. (the “Company”) issued a press release announcing that its innovative inhaled anti-SARS-CoV-2
NanoAb virtually prevented illness when administered prophylactically in preclinical in vivo study, a copy of which is furnished herewith
as Exhibit 99.1 and incorporated by reference.
This Report on Form 6-K is hereby incorporated
by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-239344) and Form F-3 (File
No. 333-240189), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
BiondVax Pharmaceuticals Ltd. |
|
|
|
Date: January 23, 2023 |
By: |
/s/ Amir Reichman |
|
|
Amir Reichman |
|
|
Chief Executive Officer |
2
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Mag 2023 a Mag 2024